WASHINGTON — A senior Republican senator is wading into the debate over a controversial drug discount program with new legislation to require more transparency from hospitals that participate.

Sen. Chuck Grassley (R-Iowa) dropped legislation Thursday that takes aim at the so-called 340B program, which forces drug companies to give some public and nonprofit hospitals discounts on medicines. Through Medicare, the federal government then reimburses the facilities for the drugs at a higher rate.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy